The recent publication in the Journal of Medicinal Chemistry by Mirati Therapeutics, ZoBio and Inixium nicely demonstrates the power of biophysics, structural biology and fragments to address an important…
9th RSC-BMCS Fragment-based Drug Discovery Meeting
In person ZoBio attended the 9th RSC-BMCS Fragment-based Drug Discovery meeting in Cambridge. The meeting focused on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs. ZoBio was represented by Pim de Vink (Scientist, Assay Development and Screening) who presented poster Screening for Fragment Molecular…
Oncodesign Services Acquires ZoBio
We are excited to announce that ZoBio will join forces with Oncodesign Services (ODS), a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services with notable expertise in oncology and immuno-inflammation.
https://www.oncodesign-services.com/
ZoBio is a Crystallography Company (Too)
Many still think of ZoBio as an NMR company. And while NMR will always have a special place in our hearts, we also have a thriving crystallography team!
Detailed and timely structural information is a cornerstone of rational drug design and X-ray crystallography plays a key role in most…